BioSpecifics Technologies Corp
BioSpecifics Technologies — Investor Presentation (January 2014)
22 slides from BioSpecifics Technologies's investor presentation, Jan 13, 2014
Slide 1: Innovators in the development & commercialization of injectable collagenase
Pa . i } ae >. sae " Innovators in the development & commercialization of “ “INJECTABLE _£ COLLAGENASE B oSpec fics January 2014 TECHNOLOGIES CORP
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are “forward-looking statements”
Slide 3: Company Overview
Company Overview BioSpecifics is a profitable, commercial-stage biopharma company developing injectable collagenase marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the US and XIAPEX® (the EU tradename for CCH) XIAFLEX Now Marketed for Two Indications in US New FDA-Approved Indi
Slide 4: Vast Therapeutic Potential
Vast Therapeutic Potential CCH provides a first-in-class, minimally invasive nonsurgical treatment option for conditions and diseases caused by collagen accumulation where current treatment options are limited BioSpecifics has positive results in 12 indications in the clinic: Dupuytren’s contracture
Slide 5: XIAFLEX for Dupuytren's Contracture
XIAFLEX for Dupuytren’s Contracture Formation of a collagen cord in the hand that causes one or more fingers to Definition & contract toward the palm, limiting range of motion of the fingers Key Complications Often results in physical disability, significantly affecting quality of life and daily act
Slide 6: XIAFLEX for Dupuytren's Contracture
XIAFLEX for Dupuytren’s Contracture sBLA for Label Expansion Filed in 4Q13 * Positive top-line data reported from Phase 3b MULTICORD (Multiple Treatment Investigation of Collagenase Optimizing the Resolution of Dupuytren’s) study Evaluated XIAFLEX for the concurrent treatment of adult Dupuytren’s co
Slide 7: XIAFLEX for Dupuytren's Contracture
XIAFLEX for Dupuytren’s Contracture Data from Multiple Studies Presented at ASSH Collagenase Optimal Reduction croupuyeren sc tonetern CORDLESS is a five-year observational study designed to assess the rates of . recurrence following treatment with XIAFLEX, as well as long-term safety and Evaluation
Slide 8: XIAFLEX for Peyronie's Disease
XIAFLEX for Peyronie’s Disease Excess of inelastic collagen causing penile curvature deformity, which can result in pain with erection, penile shortening, indentations, erectile Definition & ldyefanction and /ondifficilty witli eexucl intercourse =Incevere cases penis Key Complications can bend at 9
Slide 9: XIAFLEX for Peyronie's Disease
XIAFLEX for Peyronie’s Disease Approval Based on Positive Results from IMPRESS Trials IMPRESS" | and II clinical trial design ~ Two randomized (2:1 of 0.58 mg CCH or placebo) double-blind Phase 3 trials in over 800 patients at 64 sites in US and Australia, with 52-week follow up Men received up to 8
Slide 10: Deep Clinical Pipeline
Deep Clinical Pipeline Dupuytren’s FDA to review sBLA filed for multi-cord label expansi Contracture jek aoa . Sobi to file MAA for approval in EU Disease FREER Gopehne data expected fron phase beech Shoulder pening Chien-804 I study tin 1Q14 Lipoma ien-804 final study report in * CAEN Initiate plac
Slide 11: CCH for Canine and Human Lipomas
CCH for Canine and Human Lipomas BioSpecifics-Managed Programs Encapsulated deposits of benign fatty tumors often detected as bulges under Definition & the skin that occur in both humans and dogs Key Complications The most common benign tumors found in humans. Can be a serious health problem in dogs
Slide 12: CCH for Canine Lipomas
CCH for Canine Lipomas Chien-804 Placebo-Controlled Phase 2 Trial BioSpecifics reported data from placebo-controlled, randomized Phase 2 trial for CCH in dogs with benign subcutaneous lipomas 37 dogs randomized, single injection 1:1 CCH to placebo Primary efficacy endpoint: Relative change in lipoma
Slide 13: CCH for Human Lipomas
CCH for Human Lipomas Dose Escalation Phase 2 Clinical Trial BioSpecifics reported data from open label, dose escalation Phase 2 trial for humans with benign subcutaneous lipomas 14 patients received single injections of one of four ascending dosage groups ranging from 0.058 mg to 0.44 mg CCH — Prim
Slide 14: CCH for Uterine Fibroids
CCH for Uterine Fibroids Preclinical Studies Ongoing Definition & Key Complications Potential to be Nonsurgical Therapy Option US Market Opportunity Ongoing ork AD, Banks NK Henne MB. Sea Benign tumors with significant co- morbidities, which can include pain, decreased fertility, increased rate of m
Slide 15: Frozen Shoulder — Statistically Significant
Frozen Shoulder — Statistically Significant CCH Dose Response in Phase 2a Study 60. / \ Both the 0.58 mg(1mL) and 0.58 mg(2mL) babe "Forward Flexion cohort demonstrated statistically significant co Reber + Shoulder Abduction improvement over baseline scores vs. the [ 1 Extemal Rotation exercise-only
Slide 16: CCH for Frozen Shoulder Syndrome
CCH for Frozen Shoulder Syndrome Phase 2b Trial Initiated in 4Q13 Inflammation and thickening of shoulder Definition & capsule due to collagen accumulation, Key Complications Condition often limits the range of motion of the shoulder No FDA-approved pharmaceutical Potential to be Only therapies avai
Slide 17: CCH for Cellulite
CCH for Cellulite Top-line Data from Phase 2a Study Expected in 1Q15 Definition Significant Market Opportunity as First Nonsurgical Therapy Top-line Data from Phase 2a Study Expected in 1Q15 Phase 2a Study Based on Phase 1b Trial Source of data: Auxilium Pharmaceuticals, Ine. Skin dimpling as a resu
Slide 18: Auxilium Partnership
Auxilium Partnership BioSpecifics is partnered with Auxilium for the development and commercialization of CCH >$36M Received from Auxilium Future Payments Due to BioSpecifics from Auxilium Potential Royalties from Second Indication Auxilium Opt-In Rights Ex-US Strategic Partnerships Over $36M total
Slide 19: Corporate Highlights
Corporate Highlights Strong Intellectual Property Portfolio Long-term patent protection for injectable collagenase: * Dupuytren’s contracture: XIAFLEX has Orphan Drug protection in US until 2017; Drug product composition patent until 2028 and Biologic Exclusivity until 2022 Peyronie’s disease: Auxil
Slide 20: Consistently Profitable Annually
Consistently Profitable Annually 3Q13 Financial Highlights For the quarter For the year ended ended 09/30/13 12/31/12 (unaudited) (unaudited) Cash and equivalents, short term investments S$ 11,333,942 $ 8,503,737 Income Statement Revenues § 3,145,123 $ 11,145,078 Other income 7,134 34,634 Costs and
Slide 21: Anticipated Upcoming Milestones
Anticipated Upcoming Milestones Steady Momentum in BioSpecifics-Managed Indications Upcoming Milestones *Human Q Initiate placebo-controlled trial in 1H14 Lipomas Q Complete enrollment in placebo-controlled trial in 4Q14 *Canine Q Chien-804 final study report in 1Q14 Lipomas Q 120 day opt-in period
Slide 22: Pa . i }
Pa . i } ae >. sae " Innovators in the development & commercialization of “ “INJECTABLE _£ COLLAGENASE B oSpec fics January 2014 TECHNOLOGIES CORP
BioSpecifics Technologies — Investor Presentation (January 2014) on 6ix